XellSmart scores FDA fast track for Parkinson’s cell therapy

FDA accelerates development of XellSmart’s off-the-shelf Parkinson’s therapy, raising questions about the direction of regenerative medicine. Recently, Chinese regenerative medicine company XellSmart reached an important milestone after the US Food and Drug Administration (FDA) granted Fast Track Designation to XS411, its investigational cell therapy for Parkinson’s disease [1]. The designation is reserved for therapies that […] The post XellSmart scores FDA fast track for Parkinson’s cell therapy appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.